

## Drug Prior Authorization Criteria H.P. Acthar Gel

Inland Empire Health Plan

Line of Business: Medicaid

P & T Approval Date: February 20, 2019 Effective Date: April 1, 2019

This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee.

**Drugs Requiring Prior Authorization Review: H.P. Acthar Gel** (repository corticotropin injection)

Formulary Alternative: None

**CRITERIA:** 

H.P. ACTHAR GEL (REPOSITORY CORTICOTROPIN INJECTION)

**Covered Uses:** \*Infantile Spasms (West Syndrome)

(\*Subject to review by Clinical Pharmacist)

**Exclusion Criteria:** N/A

**Required Medical** 

**Information:** Must meet the following requirement:

a. Requested dose and duration must be consistent with FDA package

labeled recommendation or DrugDex compendia.

**Age Restriction:** Must be less than 24 months old

**Prescriber Restrictions:** Neurologist or Pediatrician

Other Criteria: N/A

**Covered Uses:** \*Multiple Sclerosis with acute exacerbation

(\*Subject to review by Clinical Pharmacist)

**Exclusion Criteria:** N/A

**Required Medical** 

**Information:** Must meet all of the following requirements:

a. Failure or clinically significant adverse effects to corticosteroid therapy (i.e. prednisone, intravenous methylprednisolone, etc.).

b. Documentation of concurrent multiple sclerosis agents (i.e. **Avonex**, **Betaseron**, **Glatiramer**, etc.).

c. Requested dose and duration must be consistent with FDA package labeled recommendation or DrugDex compendia.

Age Restriction: N/A

**Prescriber Restrictions:** Neurologist

Other Criteria: N/A

Change Control		
Date	Change	RPH
02/20/2019	Changed Format	ND
06/29/2018	Changed Format	IK
02/21/2018	<ul> <li>Renewed with no new updates/changes.</li> </ul>	СТ